439 related articles for article (PubMed ID: 16445720)
1. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Appelbaum PC
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
3. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin intermediate and resistant Staphylococcus aureus. What the nephrologist needs to know.
McDonald LC; Hageman JC
Nephrol News Issues; 2004 Oct; 18(11):63-4, 66-7, 71-2 passim. PubMed ID: 15551615
[TBL] [Abstract][Full Text] [Related]
5. Key considerations in the treatment of complicated staphylococcal infections.
Jones RN
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
[TBL] [Abstract][Full Text] [Related]
6. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial resistance in gram-positive bacteria.
Rice LB
Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S11-9; discussion S64-73. PubMed ID: 16813977
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Saravolatz LD; Pawlak J; Johnson LB
Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
[TBL] [Abstract][Full Text] [Related]
10. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
11. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.
Sievert DM; Rudrik JT; Patel JB; McDonald LC; Wilkins MJ; Hageman JC
Clin Infect Dis; 2008 Mar; 46(5):668-74. PubMed ID: 18257700
[TBL] [Abstract][Full Text] [Related]
13. Glycopeptide resistant Staphylococcus.
Witte W
J Vet Med B Infect Dis Vet Public Health; 2004; 51(8-9):370-3. PubMed ID: 15525368
[TBL] [Abstract][Full Text] [Related]
14. [Detection methods for drug-resistant bacteria in routine examination--VISA].
Kinoshita S; Nakamachi Y
Rinsho Byori; 2000 Jan; Suppl 111():69-74. PubMed ID: 10804795
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin-resistant Staphylococcus aureus--New York, 2004.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Apr; 53(15):322-3. PubMed ID: 15103297
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance in gram-positive bacteria.
Rice LB
Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
[TBL] [Abstract][Full Text] [Related]
17. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
Howden BP
Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
19. Staphylococcus aureus resistant to vancomycin--United States, 2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Jul; 51(26):565-7. PubMed ID: 12139181
[TBL] [Abstract][Full Text] [Related]
20. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.
Tiwari HK; Sen MR
BMC Infect Dis; 2006 Oct; 6():156. PubMed ID: 17067393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
